Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis (TARGET Trial): Does Ticagrelor Improve Graft Patency After Coronary Bypass?
Phase of Trial: Phase IV
Latest Information Update: 30 Jan 2018
At a glance
- Drugs Ticagrelor (Primary) ; Aspirin
- Indications Coronary artery disease; Coronary artery restenosis; Vascular graft occlusion
- Focus Therapeutic Use
- Acronyms TARGET
- 24 Jan 2018 Planned End Date changed from 1 Jun 2020 to 1 Aug 2023.
- 24 Jan 2018 Planned primary completion date changed from 1 Jun 2019 to 1 Aug 2022.
- 18 Jul 2016 Planned End Date changed from 1 Sep 2018 to 1 Jun 2020.